This excerpt taken from the TPTX 10-K filed Mar 29, 2007.
2005 Collaboration Agreement
In February 2005, we entered into a collaboration agreement with Eisai regarding our program for discovery of novel, small molecule compounds designed to delay the onset or slow the progression of Alzheimers disease. Under the agreement, Eisai has exclusive, time-limited rights of first negotiation and refusal for compounds discovered in the course of the program.
We received an initial $10.0 million cash payment from Eisai in consideration of the rights granted to Eisai under the agreement. The agreement had an initial two-year term that Eisai elected to extend for an additional 12 months for an additional fee of $5.0 million.
This excerpt taken from the TPTX 8-K filed Oct 10, 2006.
This Collaboration Agreement (hereinafter called the Agreement) made and entered into this 28th day of February 2005 (the Effective Date), by and between Neurogenetics, Inc., a corporation organized and existing under the laws of Delaware (Neurogenetics), with principal place of business at 11085 North Torrey Pines Road, La Jolla, CA 92037, the United States of America, and Eisai Co., Ltd., a corporation organized and existing under the laws of Japan (Eisai), with its registered office at 6-10 Koishikawa 4-chome, Bunkyo-ku, Tokyo 112-8088, Japan.
RELATED TOPICS for TPTX: